Assessment of the safety of regular D DAVP therapy in primary nocturnal enuresis
Assessment of the safety of regular D DAVP therapy in primary nocturnal enuresis
Summary— —A group of 7 patients with refractory primary nocturnal enuresis on long‐term DDAVP therapy (mean 13 months) were submitted to a standard water deprivation test in conjunction with a hormone profile and routine haematological and biochemical investigations. No abnormalities were demonstrated, which suggests that the drug is safe in this clinical situation.
352-353
REW, D. A.
36dcc3ad-2379-4b61-a468-5c623d796887
RUNDLE, J. S.H.
4f11ead1-8ce5-4cf7-9044-c67785d93767
April 1989
REW, D. A.
36dcc3ad-2379-4b61-a468-5c623d796887
RUNDLE, J. S.H.
4f11ead1-8ce5-4cf7-9044-c67785d93767
REW, D. A. and RUNDLE, J. S.H.
(1989)
Assessment of the safety of regular D DAVP therapy in primary nocturnal enuresis.
British Journal of Urology, 63 (4), .
(doi:10.1111/j.1464-410X.1989.tb05215.x).
Abstract
Summary— —A group of 7 patients with refractory primary nocturnal enuresis on long‐term DDAVP therapy (mean 13 months) were submitted to a standard water deprivation test in conjunction with a hormone profile and routine haematological and biochemical investigations. No abnormalities were demonstrated, which suggests that the drug is safe in this clinical situation.
This record has no associated files available for download.
More information
Published date: April 1989
Additional Information:
Copyright:
Copyright 2016 Elsevier B.V., All rights reserved.
Identifiers
Local EPrints ID: 447912
URI: http://eprints.soton.ac.uk/id/eprint/447912
ISSN: 0007-1331
PURE UUID: 5ffaf36d-8652-49f5-957b-b9f544e94187
Catalogue record
Date deposited: 25 Mar 2021 18:29
Last modified: 17 Mar 2024 03:56
Export record
Altmetrics
Contributors
Author:
J. S.H. RUNDLE
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
